AbCellera Biologics
Vancouver-based AbCellera Biologics researches and develops human antibodies using proprietary technology.
Founded
2012Vancouver-based AbCellera Biologics researches and develops human antibodies using proprietary technology.
Founded in 2012 and headquartered in Vancouver, British Columbia, AbCellera Biologics Inc. is a biotechnology firm specializing in the research and development of human antibodies. The company's core mission is to accelerate the discovery of therapeutic antibodies using its proprietary technology platform, which can develop medical countermeasures within 60 days. AbCellera's platform for single-cell screening, initially developed at the University of British Columbia, focuses on addressing urgent health challenges, including pandemic prevention.
Notable affiliations include partnerships with DARPA's Biological Technologies Office and collaborations with Viking Global Investors and ArrowMark Partners. AbCellera has achieved significant milestones, such as its prominent role in the Pandemic Prevention Platform and its public listing on Nasdaq under the ticker ABCL. With a revenue of $375.2 million in 2021 and a workforce of 386 employees, AbCellera has made substantial contributions to the biotechnology industry, particularly in rapid antibody discovery and development.
Companies similar to AbCellera Biologics include OmniAb, Single Cell Technology, Abterra Biosciences and Idbiologics.
AbCellera Biologics was founded in 2012.
AbCellera Biologics' headquarters is located in Vancouver, British Columbia, CA.
AbCellera Biologics' most recent funding round was for CA$701M (CAD) in May 2023.
As of May 24, 2023, AbCellera Biologics has raised a total of 1.1B.
AbCellera Biologics has 495 employees as of Feb 12, 2024.
Abterra Biosciences
abterrabio.com
